CYBB and COVID-19: Recent study demonstrated that patients suffering from severe COVID-19 disease, requiring intensive care unit treatment, presented higher levels of Nox2 activation, and thus, Nox2 seems to be a pivotal agent in COVID-19 aggravation [37].